REFERENCES
Berger, N.D., Gadotti, V.M., Petrov, R.R., Chapman, K., Diaz, P., and Zamponi, G.W. (2014). NMP-7 inhibits chronic inflammatory and neuropathic pain via block of Cav3.2 T-type calcium channels and activation of CB2 receptors. Mol. Pain 10 : 77.
Bernal Sierra, Y.A., Haseleu, J., Kozlenkov, A., Bégay, V., and Lewin, G.R. (2017). Genetic Tracing of Cav3.2 T-Type Calcium Channel Expression in the Peripheral Nervous System. Front. Mol. Neurosci. 10 : 70.
Bohic, M., Marics, I., Santos, C., Malapert, P., Ben-Arie, N., Salio, C., et al. (2020). Loss of bhlha9 Impairs Thermotaxis and Formalin-Evoked Pain in a Sexually Dimorphic Manner. Cell Rep.30 : 602-610.e6.
Bourinet, E., Alloui, A., Monteil, A., Barrere, C., Couette, B., Poirot, O., et al. (2005). Silencing of the Cav3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. Embo J24 : 315–24.
Bourinet, E., Francois, A., and Laffray, S. (2016). T-type calcium channels in neuropathic pain. Pain 157 Suppl 1 : S15-22.
Boyman, O., Comte, D., and Spertini, F. (2014). Adverse reactions to biologic agents and their medical management. Nat. Rev. Rheumatol.10 : 612–627.
Carbone, E., Giancippoli, A., Marcantoni, A., Guido, D., and Carabelli, V. (2006). A new role for T-type channels in fast ‘low-threshold’ exocytosis. Cell Calcium 40 : 147–154.
Chen, C.-C., Lamping, K.G., Nuno, D.W., Barresi, R., Prouty, S.J., Lavoie, J.L., et al. (2003). Abnormal coronary function in mice deficient in alpha1H T-type Ca2+ channels. Science 302 : 1416–1418.
Choe, W., Messinger, R.B., Leach, E., Eckle, V.-S., Obradovic, A., Salajegheh, R., et al. (2011). TTA-P2 is a potent and selective blocker of T-type calcium channels in rat sensory neurons and a novel antinociceptive agent. Mol. Pharmacol. 80 : 900–910.
Choi, S., Na, H.S., Kim, J., Lee, J., Lee, S., Kim, D., et al. (2007). Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes Brain Behav. 6 : 425–431.
Curtis, M.J., Alexander, S., Cirino, G., Docherty, J.R., George, C.H., Giembycz, M.A., et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. Br. J. Pharmacol. 175 : 987–993.
Curtis, M.J., Bond, R.A., Spina, D., Ahluwalia, A., Alexander, S.P.A., Giembycz, M.A., et al. (2015). Experimental design and analysis and their reporting: new guidance for publication in BJP. Br. J. Pharmacol.172 : 3461–3471.
Dalmann, R., Daulhac, L., Antri, M., Eschalier, A., and Mallet, C. (2015). Supra-spinal FAAH is required for the analgesic action of paracetamol in an inflammatory context. Neuropharmacology 91 : 63–70.
Delfini, M.-C., Mantilleri, A., Gaillard, S., Hao, J., Reynders, A., Malapert, P., et al. (2013). TAFA4, a chemokine-like protein, modulates injury-induced mechanical and chemical pain hypersensitivity in mice. Cell Rep. 5 : 378–388.
Francois, A., Kerckhove, N., Meleine, M., Alloui, A., Barrere, C., Gelot, A., et al. (2013). State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. Pain 154 : 283–293.
François, A., Schüetter, N., Laffray, S., Sanguesa, J., Pizzoccaro, A., Dubel, S., et al. (2015). The Low-Threshold Calcium Channel Cav3.2 Determines Low-Threshold Mechanoreceptor Function. Cell Rep.
García-Caballero, A., Gadotti, V.M., Stemkowski, P., Weiss, N., Souza, I.A., Hodgkinson, V., et al. (2014). The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. Neuron 83 : 1144–1158.
Graham, G.G., Davies, M.J., Day, R.O., Mohamudally, A., and Scott, K.F. (2013). The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 21 : 201–232.
Hellman, P., and Eriksson, H. (2007). Early activation markers of human peripheral dendritic cells. Hum. Immunol. 68 : 324–333.
Højsted, J., and Sjøgren, P. (2007). Addiction to opioids in chronic pain patients: a literature review. Eur. J. Pain Lond. Engl. 11 : 490–518.
Ioannidis, J.P.A., Karassa, F.B., Druyts, E., Thorlund, K., and Mills, E.J. (2013). Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat. Rev. Rheumatol. 9 : 665–673.
Jacus, M.O., Uebele, V.N., Renger, J.J., and Todorovic, S.M. (2012). Presynaptic Cav3.2 channels regulate excitatory neurotransmission in nociceptive dorsal horn neurons. J. Neurosci. Off. J. Soc. Neurosci.32 : 9374–9382.
Jarvis, M.F., Scott, V.E., McGaraughty, S., Chu, K.L., Xu, J., Niforatos, W., et al. (2014). A peripherally acting, selective T-type calcium channel blocker, ABT-639, effectively reduces nociceptive and neuropathic pain in rats. Biochem. Pharmacol. 89 : 536–544.
Kerckhove, N., Boudieu, L., Ourties, G., Bourdier, J., Daulhac, L., Eschalier, A., et al. (2019). Ethosuximide improves chronic pain-induced anxiety- and depression-like behaviors. Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol. 29 : 1419–1432.
Kerckhove, N., Mallet, C., François, A., Boudes, M., Chemin, J., Voets, T., et al. (2014). Ca(v)3.2 calcium channels: the key protagonist in the supraspinal effect of paracetamol. Pain 155 : 764–772.
Lee, I.O., and Jeong, Y.S. (2002). Effects of different concentrations of formalin on paw edema and pain behaviors in rats. J. Korean Med. Sci.17 : 81–85.
Lee, J., Kim, D., and Shin, H.-S. (2004). Lack of delta waves and sleep disturbances during non-rapid eye movement sleep in mice lacking alpha1G-subunit of T-type calcium channels. Proc. Natl. Acad. Sci. U. S. A. 101 : 18195–18199.
Matsunami, M., Miki, T., Nishiura, K., Hayashi, Y., Okawa, Y., Nishikawa, H., et al. (2012). Involvement of the endogenous hydrogen sulfide/Ca(v) 3.2 T-type Ca2+ channel pathway in cystitis-related bladder pain in mice. Br. J. Pharmacol. 167 : 917–928.
Percie du Sert, N., Ahluwalia, A., Alam, S., Avey, M.T., Baker, M., Browne, W.J., et al. (2020). Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 18 : e3000411.
Perez-Reyes, E. (2003). Molecular physiology of low-voltage-activated t-type calcium channels. Physiol. Rev. 83 : 117–161.
Picard, E., Carvalho, F.A., Agosti, F., Bourinet, E., Ardid, D., Eschalier, A., et al. (2019). Inhibition of Cav 3.2 calcium channels: A new target for colonic hypersensitivity associated with low-grade inflammation. Br. J. Pharmacol. 176 : 950–963.
Pinho-Ribeiro, F.A., Verri, W.A., and Chiu, I.M. (2017). Nociceptor Sensory Neuron-Immune Interactions in Pain and Inflammation. Trends Immunol. 38 : 5–19.
Reynders, A., Mantilleri, A., Malapert, P., Rialle, S., Nidelet, S., Laffray, S., et al. (2015). Transcriptional Profiling of Cutaneous MRGPRD Free Nerve Endings and C-LTMRs. Cell Rep. 10 : 1007–1019.
Roda, G., Jharap, B., Neeraj, N., and Colombel, J.-F. (2016). Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management. Clin. Transl. Gastroenterol. 7 : e135.
Samour, M.S., Nagi, S.S., and Mahns, D.A. (2015). Cav3.2-expressing low-threshold C fibres in human hairy skin contribute to cold allodynia–a non-TRPV1- and non-TRPM8-dependent phenomenon. Pain156 : 1566–1575.
Scanzi, J., Accarie, A., Muller, E., Pereira, B., Aissouni, Y., Goutte, M., et al. (2016). Colonic overexpression of the T-type calcium channel Cav 3.2 in a mouse model of visceral hypersensitivity and in irritable bowel syndrome patients. Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 28 : 1632–1640.
Seal, R.P., Wang, X., Guan, Y., Raja, S.N., Woodbury, C.J., Basbaum, A.I., et al. (2009). Injury-induced mechanical hypersensitivity requires C-low threshold mechanoreceptors. Nature 462 : 651–5.
Silva, J.A.P. da, Ramiro, S., Pedro, S., Rodrigues, A., Vasconcelos, J.C., and Benito-Garcia, E. (2010). Patients- and physicians- priorities for improvement. The case of rheumatic diseases. Acta Reumatol. Port.35 : 192–199.
Smith, M.D., Woodhead, J.H., Handy, L.J., Pruess, T.H., Vanegas, F., Grussendorf, E., et al. (2017). Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive, and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain. Neurochem. Res. 42 : 1995–2010.
Smolen, J.S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., et al. (2017). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis.76 : 960–977.
Smolen, J.S., Strand, V., Koenig, A.S., Szumski, A., Kotak, S., and Jones, T.V. (2016). Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. Arthritis Res. Ther. 18 : 114.
Snutch, T.P., and Zamponi, G.W. (2018). Recent advances in the development of T-type calcium channel blockers for pain intervention. Br. J. Pharmacol. 175 : 2375–2383.
Stirling, L.C., Forlani, G., Baker, M.D., Wood, J.N., Matthews, E.A., Dickenson, A.H., et al. (2005). Nociceptor-specific gene deletion using heterozygous NaV1.8-Cre recombinase mice. Pain 113 : 27–36.
Sturgeon, J.A., Finan, P.H., and Zautra, A.J. (2016). Affective disturbance in rheumatoid arthritis: psychological and disease-related pathways. Nat. Rev. Rheumatol. 12 : 532–542.
Taylor, P., Manger, B., Alvaro-Gracia, J., Johnstone, R., Gomez-Reino, J., Eberhardt, E., et al. (2010). Patient perceptions concerning pain management in the treatment of rheumatoid arthritis. J. Int. Med. Res.38 : 1213–1224.
Todorovic, S.M., and Jevtovic-Todorovic, V. (2011). T-type voltage-gated calcium channels as targets for the development of novel pain therapies. Br. J. Pharmacol. 163 : 484–495.
Urien, L., Gaillard, S., Lo Re, L., Malapert, P., Bohic, M., Reynders, A., et al. (2017). Genetic ablation of GINIP-expressing primary sensory neurons strongly impairs Formalin-evoked pain. Sci. Rep. 7 : 43493.
Walsh, D.A., and McWilliams, D.F. (2014). Mechanisms, impact and management of pain in rheumatoid arthritis. Nat. Rev. Rheumatol.10 : 581–592.
Weyand, C.M., and Goronzy, J.J. (2021). The immunology of rheumatoid arthritis. Nat. Immunol. 22 : 10–18.
Xanthos, D.N., and Sandkühler, J. (2014). Neurogenic neuroinflammation: inflammatory CNS reactions in response to neuronal activity. Nat. Rev. Neurosci. 15 : 43–53.
Zhou, X., Yang, W., and Li, J. (2006). Ca2+- and protein kinase C-dependent signaling pathway for nuclear factor-kappaB activation, inducible nitric-oxide synthase expression, and tumor necrosis factor-alpha production in lipopolysaccharide-stimulated rat peritoneal macrophages. J. Biol. Chem. 281 : 31337–31347.
Ziegler, D., Duan, W.R., An, G., Thomas, J.W., and Nothaft, W. (2015). A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain. Pain 156 : 2013–2020.